Literature DB >> 23404940

Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome.

Sebastien X Joncas1, Paul Poirier, Jean-Luc Ardilouze, Nathalie Carrier, Tania Fayad, Paul Farand.   

Abstract

OBJECTIVE: The use of a weight-based nomogram is considered as standard care for prescribing appropriate doses of unfractionated heparin (UFH). Because of the need for multiple other medications that may affect bleeding and that clinical data have relied on similar dosing algorithms, maximum initial bolus and infusion rates have been suggested (capped initial dose). Whether these weight-based heparin nomograms properly address therapeutic dosing in obese patients remains questionable. DESIGN AND METHODS: Thirty patients treated for acute coronary syndrome and weighing ≥110 kg were retrospectively compared with 90 controls (three groups of 30 patients, weighting 50-69.9, 70-89.9, or 90-109.9 kg), all treated with UFH, July 2008 to April 2009. The primary end point was the time required to obtain a threshold activated partial thromboplastin time (aPTT).
RESULTS: Mean time to achieve threshold aPTT was longer for obese patients weighing ≥110 kg than for controls (31.47 vs. 12.89 hours; P < 0.0001). At 24 hours, 63% of obese patients weighing ≥110 kg had not reached threshold aPTT vs. 7% of controls (P < 0.0001). However, threshold infusion rate did not differ between weight categories (13.0 vs. 13.1 U/kg/h; P = NS) and approximated the initial infusion rate recommended by nomograms without applying the dose cap (12 U/kg/h).
CONCLUSIONS: Adequate anticoagulation time doubled in patients weighing ≥110 kg, suggesting that these patients were not receiving appropriate heparin doses initially to achieve threshold aPTT rapidly. Using initial infusion rate recommended by a nomogram without capping for total body weight is suggested as acceptable in this study. This approach should be further evaluated in a prospective study.
Copyright © 2012 The Obesity Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404940     DOI: 10.1002/oby.20029

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  5 in total

1.  Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose.

Authors:  Xia Hong; Pei-Ren Shan; Wei-Jian Huang; Qian-Li Zhu; Fang-Yi Xiao; Sheng Li; Hao Zhou
Journal:  J Clin Lab Anal       Date:  2014-11-25       Impact factor: 2.352

2.  [Coagulation diagnostics in the clinical routine-part 2 : Monitoring of anticoagulation treatment, new-onset thrombocytopenia and thrombophilia].

Authors:  Michael Metze; Martin Platz; Christian Pfrepper; Sirak Petros
Journal:  Inn Med (Heidelb)       Date:  2022-05-19

Review 3.  Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.

Authors:  Tiffany M Powell-Wiley; Paul Poirier; Lora E Burke; Jean-Pierre Després; Penny Gordon-Larsen; Carl J Lavie; Scott A Lear; Chiadi E Ndumele; Ian J Neeland; Prashanthan Sanders; Marie-Pierre St-Onge
Journal:  Circulation       Date:  2021-04-22       Impact factor: 29.690

4.  Derivation and Validation of Age- and Body Mass Index-Adjusted Weight-Based Unfractionated Heparin Dosing.

Authors:  James W Schurr; Anne-Marie Muske; Craig A Stevens; Sarah E Culbreth; Katelyn W Sylvester; Jean M Connors
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

5.  A real-world, multicenter assessment of drugs requiring weight-based calculations in overweight, adult critically ill patients.

Authors:  Sandra L Kane-Gill; Nicholas P Wytiaz; Lisa M Thompson; Karina Muzykovsky; Mitchell S Buckley; Henry Cohen; Amy L Seybert
Journal:  ScientificWorldJournal       Date:  2013-11-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.